Hypoxia increases breast cancer cell-induced lymphatic endothelial cell migration

Neoplasia

Volumn 10, Issue 4, 2008, Pages 380-388

  Mikhaylova, Maria ^a   Mori, Noriko ^a   Wildes, Flonné B ^a   Walczak, Piotr ^a   Gimi, Barjor ^a,b   Bhujwalla, Zaver M ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER CELL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REOXYGENATION;

EID: 41649115197     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07854     Document Type: Article

References (42)

1. Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, Foster R, Gardner B, Lerner H, and Margolese R (1983). Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 52, 1551-1557.
2. Van den Eynden GG, Van der Auwera I, Van Laere SJ, Huygelen V, Colpaert CG, van Dam P, Dirix LY, Vermeulen PB, and Van Marck EA (2006). Induction of lymphangiogenesis in and around axillary lymph node metastases of patients with breast cancer. Br J Cancer 95, 1362-1366.
3. Foster RS Jr (1996). The biologic and clinical significance of lymphatic metastases in breast cancer. Surg Oncol Clin N Am 5, 79-104.
4. Nathanson SD (2003). Insights into the mechanisms of lymph node metastasis. Cancer 98, 413-423.
5. Pepper MS, Tille JC, Nisato R, and Skobe M (2003). Lymphangiogenesis and tumor metastasis. Cell Tissue Res 314, 167-177.
6. Baldwin ME, Stacker SA, and Achen MG (2002). Molecular control of lymphangiogenesis. Bioessays 24, 1030-1040.
7. Stacker SA, Achen MG, Jussila L, Baldwin ME, and Alitalo K (2002). Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2, 573-583.
8. Stacker SA, Baldwin ME, and Achen MG (2002). The role of tumor lymphangiogenesis in metastatic spread. FASEB J 16, 922-934.
9. Cassella M and Skobe M (2002). Lymphatic vessel activation in cancer. Ann NY Acad Sci 979, 120-130.
10. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, and Alitalo K (1996). A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15, 1751.
11. Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Alitalo K, and Stacker SA (1998). Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 95, 548-553.
12. Mohammed RA, Green A, El-Shikh S, Paish EC, Ellis IO, and Martin SG (2007). Prognostic significance of vascular endothelial cell growth factors-A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. Br J Cancer 96, 1092-1100.
13. Zeng Y, Opeskin K, Goad J, and Williams ED (2006). Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis. Cancer Res 66, 9566-9575.
14. Whitehurst B, Flister MJ, Bagaitkar J, Volk L, Bivens CM, Pickett B, Castro-Rivera E, Brekken RA, Gerard RD, and Ran S (2007). Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model. Int J Cancer 121, 2181-2191.
15. Swartz MA and Skobe M (2001). Lymphatic function, lymphangiogenesis, and cancer metastasis. Microsc Res Tech 55, 92-99.
16. Fukumura D and Jain RK (2007). Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 101, 937-949.
17. Vaupel P and Mayer A (2007). Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26, 225-239.
18. Semenza GL (2000). Expression of hypoxia-inducible factor 1: mechanisms and consequences. Biochem Pharmacol 59, 47-53.
19. Decaestecker C, Debeir O, Van Ham P, and Kiss R (2007). Can anti-migratory drugs be screened in vitro? A review of 2D and 3D assays for the quantitative analysis of cell migration. Med Res Rev 27, 149-176.
20. Gimi B, Mori N, Ackerstaff E, Frost EE, Bulte JW, and Bhujwalla ZM (2006). Noninvasive MRI of endothelial cell response to human breast cancer cells. Neoplasia 8, 207-213.
21. Iivanainen E, Kahari VM, Heino J, and Elenius K (2003). Endothelial cell-matrix interactions. Microsc Res Tech 60, 13-22.
22. Ji RC (2006). Lymphatic endothelial cells, lymphangiogenesis, and extracellular matrix. Lymphat Res Biol 4, 83-100.
23. Shields JD, Emmett MS, Dunn DB, Joory KD, Sage LM, Rigby H, Mortimer PS, Orlando A, Levick JR, and Bates DO (2007). Chemokine-mediated migration of melanoma cells toward lymphatics - a mechanism contributing to metastasis. Oncogene 26, 2997-3005.
24. Cailleau R, Young R, Olive M, and Reeves WJ Jr (1974). Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 53, 661-674.
25. Paine TM, Soule HD, Pauley RJ, and Dawson PJ (1992). Characterization of epithelial phenotypes in mortal and immortal human breast cells. Int J Cancer 50, 463-473.
26. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, and Josephson L (1990). Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 175, 489-493.
27. Frank JA, Zywicke H, Jordan EK, Mitchell J, Lewis BK, Miller B, Bryant LH Jr, and Bulte JW (2002). Magnetic intracellular labeling of mammalian cells by combining (FDA-approved) superparamagnetic iron oxide MR contrast agents and commonly used transfection agents. Acad Radiol 9, S484-S487.
28. Banerji S, Ni J, Wang SX, Clasper S, Su J, Tammi R, Jones M, and Jackson DG (1999). LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 144, 789-801.
29. Irigoyen M, Anso E, Martinez E, Garayoa M, Martinez-Irujo JJ, and Rouzaut A (2007). Hypoxia alters the adhesive properties of lymphatic endothelial cells. A transcriptional and functional study. Biochim Biophys Acta 1773, 880-890.
30. Ota H, Katsube KI, Ogawa JI, and Yanagishita M (2007). Hypoxia/Notch signaling in primary culture of rat lymphatic endothelial cells. FEBS Lett 581, 5220-5226.
31. Yamaguchi H, Wyckoff J, and Condeelis J (2005). Cell migration in tumors. Curr Opin Cell Biol 17, 559-564.
32. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, and Detmar M (2001). Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7, 192-198.
33. Negrini D, Passi A, de Luca G, and Miserocchi G (1996). Pulmonary interstitial pressure and proteoglycans during development of pulmonary edema. Am J Physiol 270, H2000-H2007.
34. Gunningham SP, Currie MJ, Han C, Turner K, Scott PA, Robinson BA, Harris AL, and Fox SB (2001). Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia. Cancer Res 61, 3206-3211.
35. Schoppmann SF, Fenzl A, Schindl M, Bachleitner-Hofmann T, Nagy K, Gnant M, Horvat R, Jakesz R, and Birner P (2006). Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer. Breast Cancer Res Treat 99, 135-141.
36. McColl BK, Stacker SA, and Achen MG (2004). Molecular regulation of the VEGF family - inducers of angiogenesis and lymphangiogenesis. APMIS 112, 463-480.
37. Shim H, Lau SK, Devi S, Yoon Y, Cho HT, and Liang Z (2006). Lower expression of CXCR4 in lymph node metastases than in primary breast cancers: potential regulation by ligand-dependent degradation and HIF-1alpha. Biochem Biophys Res Commun 346, 252-258.
38. Piovan E, Tosello V, Indraccolo S, Masiero M, Persano L, Esposito G, Zamarchi R, Ponzoni M, Chieco-Bianchi L, Dalla-Favera R, et al. (2007). Differential regulation of hypoxia-induced CXCR4 triggering during B-cell development and lymphomagenesis. Cancer Res 67, 8605-8614.
39. Parr C, Watkins G, Boulton M, Cai J, and Jiang WG (2005). Placenta growth factor is over-expressed and has prognostic value in human breast cancer. Eur J Cancer 41, 2819-2827.
40. Green CJ, Lichtlen P, Huynh NT, Yanovsky M, Laderoute KR, Schaffner W, and Murphy BJ (2001). Placenta growth factor gene expression is induced by hypoxia in fibroblasts: a central role for metal transcription factor-1. Cancer Res 61, 2696-2703.
41. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, et al. (2007). Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131, 463-475.
42. Raman V, Artemov D, Pathak AP, Winnard PT Jr, McNutt S, Yudina A, Bogdanov A Jr, and Bhujwalla ZM (2006). Characterizing vascular parameters in hypoxic regions: a combined magnetic resonance and optical imaging study of a human prostate cancer model. Cancer Res 66, 9929-9936.